title: Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
abstract: Hemophilia B Fukuoka, a moderately severe bleeding disorder, is a naturally occurring mutant of factor IX. Plasma from our patient had 3% clotting activity even though 64% of factor IX antigen was present. The purified mutant protein was cleaved normally by factor Xla, factor VIIa-tissue factor complex, or RVV-X (factor X-activating enzyme from Russell's viper venom), yielding a two-chain factor IXa. Amino acid composition and sequence analyses of one of the lysyl endopeptidase peptides derived from factor IX Fukuoka revealed that Asn92 in the second epidermal growth factor (EGF)-like domain had been replaced by His. The active site of the factor IXa Fukuoka was normally competent for the incorporation of p-aminobenzamidine and for the hydrolysis of a synthetic substrate, N alpha-benzyloxycarbonyl-L-arginine p-nitrobenzyl ester. Factor Xa formation by factor IXa Fukuoka was only 8% of the normal factor IXa, even in the presence of polylysine, and only 0.2% of the normal in the system containing phospholipids, Ca2+, and factor VIIIa, thereby indicating a functional defect in interaction of the mutant with factors VIIIa/X. Furthermore, catalytic efficiency (kcat/Km) of factor IXa Fukuoka toward factor X in the presence of Ca2+, phospholipids, and factor VIIIa was only 2.3% of the normal factor IXa. These results suggest that an Asn-to-His substitution at position 92 in the second EGF-like domain of factor IX Fukuoka would have an untoward effect on the specific conformational state of factor IX for binding with factors VIIIa/X.
authors.affiliation: Department of Molecular Biology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Takeya
authors.forename: T
authors.initials: T
authors.lastname: Miyata
authors.forename: K
authors.initials: K
authors.lastname: Suehiro
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: Y
authors.initials: Y
authors.lastname: Niho
authors.forename: S
authors.initials: S
authors.lastname: Iwanaga
mesh_terms: D000328:Adult; D001216:Asparagine / Q000235:genetics; D001550:Benzamidines / Q000378:metabolism; D001779:Blood Coagulation Factors / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000235:genetics; D004950:Esterases / Q000378:metabolism; D005164:Factor IX / Q000235:genetics* / Q000378:metabolism; D015942:Factor VIIa / Q000378:metabolism*; D005170:Factor X / Q000378:metabolism*; D002836:Hemophilia B / Q000235:genetics* / Q000378:metabolism; D006639:Histidine / Q000235:genetics; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D008297:Male; D009154:Mutation; D010449:Peptide Mapping
chemical_list: D001550:Benzamidines; D001779:Blood Coagulation Factors; D006639:Histidine; D004815:Epidermal Growth Factor; C006500:4-aminobenzamidine; D001216:Asparagine; D005164:Factor IX; D005170:Factor X; D004950:Esterases; D015942:Factor VIIa